Merck Serono resubmits oral MS therapy to FDA
pharmafile | June 8, 2010 | News story | Research and Development | Cladribine, MS, Merck KGaA
Merck Serono has re-submitted its oral multiple sclerosis therapy cladribine to US regulators.
Merck Serono, a Swiss division of Merck KGaA, had previously been sent a ‘refuse to file’ letter from the FDA in November last year due to serious ‘omissions or inadequacies’ in the document submitted.
Cladribine is a small molecule that may interfere with the behaviour and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.
The drug is in fierce competition with Novartis’ MS oral therapy Gilenia, which recently received a boost from new trial data and has been awarded priority review status from the FDA.
This has however been pushed back by three months as the US regulator requires more time to analyse Gilenia’s trial data.
Ben Adams
Related Content
Exscientia enters AI drug discovery collaboration with Merck KGaA
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its …
Genentech shares results from phase 3 trial for MS treatment
Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus …